Cenerimod is an investigational new drug that is being evaluated for the treatment of systemic lupus erythematosus.[1] It is a sphingosine-1-phosphate receptor modulator.[2]
References
- ^ “Cenerimod – Idorsia Pharmaceuticals”. AdisInsight. Springer Nature Switzerland AG.
- ^ Piali L, Birker-Robaczewska M, Lescop C, Froidevaux S, Schmitz N, Morrison K, et al. (December 2017). “Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties”. Pharmacology Research & Perspectives. 5 (6). doi:10.1002/prp2.370. PMC 5723703. PMID 29226621.